Apsibin (Capecitabine) coated tablets 500 mg. 120

$395.40

Manufacturer: India

Indicated for:

Mammary cancer:

  • local advanced or metastatic breast cancer, in combination with docetaxel after ineffective chemotherapy, including anthracycline drugs;
  • local advanced or metastatic breast cancer, with the ineffectiveness of chemotherapy, including taxanes and anthracycline drugs, or if there is a contraindication to anthracycline therapy.

Colon cancer, colorectal cancer:

  • colon cancer, in adjuvant therapy,
  • a first-line drug for the treatment of metastatic colorectal cancer.

Cancer of the esophagus and stomach:

  • first-line drug for the treatment of advanced cancer of the esophagus and stomach.
Category:

Description

Ingredients:

active ingredient: capecitabine;

1 tablet contains 150 mg or 500 mg of capecitabine;

Excipients: croscarmellose sodium, microcrystalline cellulose (Avicel PH112), hypromellose (6 cps), lactose DCL22, magnesium stearate, opadra pink 03A540004 (hypromellose, titanium dioxide (E 171), talc, iron oxide red (E172), iron oxide yellow (E172)) – for tablets of 150 mg, opadra pink 03A540003 (hypromellose, titanium dioxide (E 171), talc, iron oxide red (E172), iron oxide yellow (E172)) – for tablets of 500 mg.

Indications.

Mammary cancer:

  • local advanced or metastatic breast cancer, in combination with docetaxel after ineffective chemotherapy, including anthracycline drugs;
  • local advanced or metastatic breast cancer, with the ineffectiveness of chemotherapy, including taxanes and anthracycline drugs, or if there is a contraindication to anthracycline therapy.

Colon cancer, colorectal cancer:

  • colon cancer, in adjuvant therapy,
  • a first-line drug for the treatment of metastatic colorectal cancer.

Cancer of the esophagus and stomach:

  • first-line drug for the treatment of advanced cancer of the esophagus and stomach.

Contraindications.

Severe, including unexpected, reactions to treatment with fluoropyrimidines. Hypersensitivity to capecitabine or to any component of the drug, or to fluorouracil. Known deficiency of dihydropyrimidine dehydrogenase. Severe leukopenia, neutropenia, thrombocytopenia. Severe liver dysfunction. Severe renal failure (creatinine clearance <30 ml/min). Simultaneous reception with sorivudine or its structural analogues such as brivudine.

Method of application and dose.

Standard dosage

The drug is taken orally, no later than 30 minutes after a meal, with water.

Monotherapy

Colon cancer, colorectal cancer, and breast cancer The recommended daily dose of capecitabine is 2500 mg/m2 and is administered in three-week cycles; take daily for 2 weeks, then take a week break. The total daily dose of capecitabine is divided into two doses (1250 mg/m2 in the morning and evening).